Abionic

Coming – October 22

A 72-Hour Head Start on Sepsis

Date and Time

October 22

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

A Fireside Chat with Patrick Pestalozzi, CEO, Abionic

Sepsis affects millions of people and can progress with frightening speed. One of the biggest challenges is that its earliest symptoms are often nonspecific, making it difficult for clinicians to identify which patients are beginning to deteriorate.

Abionic is developing a fundamentally different approach: identify the risk earlier.

The company’s abioSCOPE® point-of-care platform measures Pancreatic Stone Protein (PSP), a biomarker that may begin rising 48 to 72 hours before clinical diagnosis. Using a single drop of blood, the system can deliver a quantitative result in just seven minutes.

That earlier warning could be particularly important in burn, trauma, surgical, and other high-acuity patients, where inflammation can make infection difficult to distinguish.

Join us for a Fireside Chat with Abionic CEO Patrick Pestalozzi to explore:
  • Why sepsis remains so difficult to identify early
  • How PSP could create a new early-warning window
  • Why rapid bedside testing could change clinical decision-making
  • The science behind Abionic’s patented nanofluidic platform
  • Abionic’s path toward broader U.S. adoption
  • How the abioSCOPE platform could ultimately extend beyond sepsis to other time-sensitive biomarkers

Abionic has already established an FDA-cleared point-of-care platform, automated manufacturing capacity, and a growing body of clinical evidence. The next step is demonstrating how earlier information can translate into better clinical outcomes and hospital economics.

The opportunity is not simply to diagnose sepsis faster. It is to give clinicians more time to act.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.